Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Related articles:
Related suggestion:
Murder trial opens in death of DetroitMichelle Yeoh shines in VERY quirky tin foilVladimir Putin is sworn in for his fifth term as president at glittering ceremony in front of handDonald Trump moves much of his White House campaign to New YorkJudge dismisses lawsuit by mother who said school hid teen's gender expressionRachel Reeves hints Labour's 'antiPGA Tour goes to Quail Hollow ahead of PGA Championship. Nelly Korda goes for 6 in a rowMinnesota ethics panel to consider how to deal with senator charged with burglaryDelhi notches crucial 20Scientists are learning the basic building blocks of sperm whale language after years of effort
1.1266s , 6500.671875 kb
Copyright © 2024 Powered by Lilly rides Mounjaro, Zepbound to better ,Culture Chronicle news portal